BRAF and colorectal cancer: Since our results showed that miR-193a-3p was identified as a mutant-BRAF-specific miRNA, the worse outcome of colorectal cancer patients with the down-regulation of miR-193a-3p from anti-EGFR therapy may be confounded by the BRAF-mutation status.